Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 378 Show results per page	View Search Criteria \| Help With Results


1.		p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				18 to 75				Other				ASSO OE-1 EudraCT 2006-006647-31, NCT00525200


2.		Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				D7913C00046 NCT00536107


3.		Yunzhi as Dietary Supplement in Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				YUNZHI-BC NCT00647075

Last Modified: 4/29/2008 First Published: 12/16/2005


4.		Phase II/III Randomized Pilot Study of Androgen Suppression (AS) Alone Versus AS in Varying Combinations With Zoledronate, Docetaxel, Prednisolone, and/or Celecoxib in Patients With Locally Advanced or Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				Not specified				Other				MRC-STAMPEDE EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476


5.		Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				17 to 75				Pharmaceutical / Industry				PH-CP010 NCT00518869

Last Modified: 8/21/2008 First Published: 9/1/2001


6.		Phase III Randomized Study of Consolidation Therapy With or Without Strontium Chloride Sr 89 After Induction Chemotherapy in Patients With Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				NCI				MDA-ID-00156 NCI-3410, 3410, NCT00024167

Last Modified: 10/16/2006 First Published: 2/1/2002


7.		Phase III Randomized Study of Neoadjuvant Docetaxel and Cisplatin With or Without Radiotherapy in Patients With Stage IIIA Non-Small Cell Lung Cancer and Mediastinal Lymph Node Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 to 75				Other				SWS-SAKK-16/00 EU-20138, NCT00030771

Last Modified: 5/27/2008 First Published: 7/1/2002


8.		Phase III Randomized Study of Cisplatin and Fluorouracil With Versus Without Ad5CMV-p53 Gene Therapy (INGN 201) in Patients With Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck (T302)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				INTROGEN-T302 UCLA-0312111-01, NCT00041626

Last Modified: 8/9/2007 First Published: 10/1/2002


9.		Phase III Randomized Study of Fluorouracil, Epirubicin, and Cyclophosphamide Versus Docetaxel, Epirubicin, and Cyclophosphamide in Women With Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				LMU-ADEBAR EU-20221, NCT00047099

Last Modified: 12/20/2006 First Published: 2/21/2003


10.		Phase III Randomized Study of Neoadjuvant Releasing Factor Agonist Therapy and Antiandrogen Therapy With or Without Docetaxel And Estramustine in Patients With Locally Advanced Prostate Cancer or With A High Risk of Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 80				Other				FRE-FNCLCC-GETUG-12/0203 EU-20238, NCT00055731

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute